Print
|
Close
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Active:
Yes
Cancer Type:
Stomach/ Gastric Cancer
NCT ID:
NCT04725994
Trial Phases:
Phase I
Phase II
Protocol IDs:
ID-VDP-103 (primary)
NCI-2021-09611
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Idience Co., Ltd.
NCI Full Details:
http://clinicaltrials.gov/show/NCT04725994
Summary
This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of
IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in
patients with advanced gastric cancer.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.